Differential agar medium (A7) for identification of Ureaplasma urealyticum (human T mycoplasmas) in primary cultures of clinical material von Shepard, M C, Lunceford, C D

Volltext

Serological Typing of Ureaplasma urealyticum Isolates from Urethritis Patients by an Agar Growth Inhibition Method von Shepard, M C, Lunceford, C D

Volltext

Unusual Colonies of Ureaplasma urealyticum (T Mycoplasmas) in Primary Agar Cultures of Certain Urine Specimens von Shepard, M C, Lunceford, C D

Volltext

Occurrence of Urease in T Strains of Mycoplasma von Shepard, M C, Lunceford, C D

Volltext

Mycoplasma species in a dysplasia clinic population von Lyons, J.F., Shepard, M.C., Daane, T.A., Wurzel, J.F., Lunceford, C.D.

Volltext

T-strain Mycoplasma. Selective inhibition by erythromycin in vitro von Shepard, M C, Lunceford, C D, Baker, R L

Volltext

Effect of pH on Human Mycoplasma Strains von SHEPARD, M C, LUNCEFORD, C D

Volltext

Urease color test medium U-9 for the detection and identification of "T" mycoplasms in clinical material von Shepard, M C, Lunceford, C D

Volltext

Urease Color Test Medium U-9 for the Detection and Identification of “T” Mycoplasmas in Clinical Material von Shepard, Maurice C., Lunceford, Carl D.

Volltext

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma von Daud, Adil I, Wolchok, Jedd D, Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S, Ribas, Antoni, Hodi, F Stephen, Joshua, Anthony M, Kefford, Richard, Hersey, Peter, Joseph, Richard, Gangadhar, Tara C, Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K, Li, Xiaoyun Nicole, Emancipator, Kenneth, Dolled-Filhart, Marisa, Kang, S Peter, Ebbinghaus, Scot, Hamid, Omid

Volltext

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC von Mok, T.S.K., Lopes, G., Cho, B.C., Kowalski, D.M., Kasahara, K., Wu, Y.-L., de Castro, G., Turna, H.Z., Cristescu, R., Aurora-Garg, D., Loboda, A., Lunceford, J., Kobie, J., Ayers, M., Pietanza, M.C., Piperdi, B., Herbst, R.S.

Volltext

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC von Garassino, Marina C., Gadgeel, Shirish, Novello, Silvia, Halmos, Balazs, Felip, Enriqueta, Speranza, Giovanna, Hui, Rina, Garon, Edward B., Horinouchi, Hidehito, Sugawara, Shunichi, Rodriguez-Abreu, Delvys, Reck, Martin, Cristescu, Razvan, Aurora-Garg, Deepti, Loboda, Andrey, Lunceford, Jared, Kobie, Julie, Ayers, Mark, Piperdi, Bilal, Pietanza, M. Catherine, Paz-Ares, Luis

Volltext

An accessible pharmacodynamic transcriptional biomarker for notch target engagement von Tanis, KQ, Podtelezhnikov, AA, Blackman, SC, Hing, J, Railkar, RA, Lunceford, J, Klappenbach, JA, Wei, B, Harman, A, Camargo, LM, Shah, S, Finney, EM, Hardwick, JS, Loboda, A, Watters, J, Bergstrom, DA, Demuth, T, Herman, GA, Strack, PR, Iannone, R

Volltext

LBA79Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials von Herbst, R S, Lopes, G, Kowalski, D M, Nishio, M, Wu, Y-L, de Castro Junior, G, Baas, P, Kim, D-W, Gubens, M A, Cristescu, R, Aurora-Garg, D, Albright, A, Ayers, M, Loboda, A, Lunceford, J, Kobie, J, Lubiniecki, G M, Pietanza, M C, Piperdi, B, Mok, T S K

Volltext

LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407 von Paz-Ares, L, Langer, C J, Novello, S, Halmos, B, Cheng, Y, Gadgeel, S M, Hui, R, Sugawara, S, Borghaei, H, Cristescu, R, Aurora-Garg, D, Albright, A, Loboda, A, Kobie, J, Lunceford, J, Ayers, M, Lubiniecki, G M, Pietanza, M C, Piperdi, B, Garassino, M C

Volltext

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC von Langer, C., Gadgeel, S., Borghaei, H., Patnaik, A., Powell, S., Gentzler, R., Yang, J.C., Gubens, M., Sequist, L., Awad, M., Cristescu, R., Aurora-Garg, D., Albright, A., Loboda, A., Kobie, J., Lunceford, J., Ayers, M., Lubiniecki, G., Piperdi, B., Pietanza, M.C., Papadimitrakopoulou, V.

Volltext

Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028) von Ott, P.A., Bang, Y-J., Razak, A.R.A., Bennouna, J., Soria, J-C., Rugo, H.S., Cohen, R.B., O'Neil, B.H., Mehnert, J.M., Lopez, J., Doi, T., van Brummelen, E., Levitan, D., Zhao, G., Emancipator, K., Stein, K., Joe, A., Ayers, M., Lunceford, J., Piha-Paul, S.A.

Volltext

Non-mitochondrial complex I proteins in a hydrogenosomal oxidoreductase complex von Johnson, Patricia J, Dyall, Sabrina D, Yan, Weihong, Delgadillo-Correa, Maria G, Lunceford, Adam, Loo, Joseph A, Clarke, Catherine F

Volltext

Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 von Kefford, Richard, Ribas, Antoni, Hamid, Omid, Robert, Caroline, Daud, Adil, Wolchok, Jedd D., Joshua, Anthony M., Hodi, F. Stephen, Gangadhar, Tara C., Hersey, Peter, Weber, Jeffrey S., Dronca, Roxana Stefania, Patnaik, Amita, Zarour, Hassane M., Dolled-Filhart, Marisa, Lunceford, Jared, Emancipator, Kenneth, Ebbinghaus, Scot, Kang, Soonmo Peter, Hwu, Wen-Jen

Volltext

Multivessel off-pump revascularization in patients with significant left main coronary artery stenosis: early and midterm outcome analysis von Beauford, Robert B, Saunders, Craig R, Lunceford, Troy Adam, Niemeier, Leo A, Shah, Shamji, Karanam, Ravindra, Prendergast, Thomas, Burns, Paul, Sardari, Frederick, Goldstein, Daniel J

Volltext